Title: A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Authors: Aghajanian, Carol; Bell-McGuinn, Katherine M.; Burris, Howard A.; Siu, Lillian L.; Stayner, Lee-Ann; Wheler, Jennifer J.; Hong, David S.; Kurkjian, Carla; Pant, Shubham; Santiago-Walker, Ademi; Gauvin, Jennifer L.; Antal, Joyce M.; Opalinska, Joanna B.; Morris, Shannon R.; Infante, Jeffrey R.
Publication: Investigational New Drugs, 2018, Vol 36, Issue 6, p1016
ISSN: 0167-6997
Publication type: Academic Journal
DOI: 10.1007/s10637-018-0591-z

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.

Aghajanian, Carol; Bell-McGuinn, Katherine M.; Burris, Howard A.; Siu, Lillian L.; Stayner, Lee-Ann; Wheler, Jennifer J.; Hong, David S.; Kurkjian, Carla; Pant, Shubham; Santiago-Walker, Ademi; Gauvin, Jennifer L.; Antal, Joyce M.; Opalinska, Joanna B.; Morris, Shannon R.; Infante, Jeffrey R.